Dana-Farber Cancer Institute is running a clinical trial to test drugs called Obinutuzumab and Ibrutinib to treat chronic lymphocytic leukemia. This research study is evaluating a combination of two drugs, ibrutinib and obinutuzumab, as a possible treatment for Chronic Lymphocytic Leukemia (CLL).
The drugs are Obinutuzumab and Ibrutinib.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||50 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase Ib Study of Ibrutinib in Combination With Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia|
|Actual Study Start Date :||December 2015|
|Estimated Primary Completion Date :||December 2018|
|Estimated Study Completion Date :||August 2021|
For enrollment please visit www.clinicaltrials.gov.